Cytek Biosciences (NASDAQ:CTKB – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare Cytek Biosciences to similar businesses based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, earnings and profitability.
Volatility and Risk
Cytek Biosciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Cytek Biosciences’ rivals have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Valuation & Earnings
This table compares Cytek Biosciences and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cytek Biosciences | $201.49 million | -$66.54 million | -8.76 |
| Cytek Biosciences Competitors | $2.27 billion | $55.88 billion | -7.36 |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Cytek Biosciences and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cytek Biosciences | 1 | 1 | 2 | 0 | 2.25 |
| Cytek Biosciences Competitors | 957 | 3187 | 5522 | 178 | 2.50 |
Cytek Biosciences presently has a consensus target price of $5.67, suggesting a potential upside of 2.66%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 0.01%. Given Cytek Biosciences’ higher possible upside, equities research analysts clearly believe Cytek Biosciences is more favorable than its rivals.
Insider & Institutional Ownership
69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 53.5% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Cytek Biosciences and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cytek Biosciences | -39.10% | -13.13% | -9.56% |
| Cytek Biosciences Competitors | -538.84% | 77.01% | -13.58% |
Summary
Cytek Biosciences rivals beat Cytek Biosciences on 8 of the 13 factors compared.
About Cytek Biosciences
Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
